The giant cell tumor of bone (GCTB) was described by Cooper and Travers in 1818. It is considered a locally aggressive benign bone tumor with tendency for high recurrence. GCTB represents approximately 5-10% of all primary bone tumors. It typically occurs in 30-40 years of age and is slightly more common in female, also is higher incidence rate in Southeast Asia than Western. The most common GCTB is involved in the epiphyseal regions of long bones, particularly the distal femur and the proximal tibia. Primary malignant turn and distant lung metastasis are about 1% and 3% in GCTB patients, respectively.

The principal symptoms are pain and swelling which are caused by cortical bone destruction and tumor expansion. Addition, joint effusion and limited range of motion are also possible. Pathological fracture shows aggressive progression of disease. The definitive diagnosis is confirmed by histological method. This benign tumor has characteristic multinucleated osteoclast-type giant cells.

There is still not a consensus in surgical treatment of grade 3 GCTB between a wide excision and an extended intralesional excision which it is all about balance between eliminating the tumor and preserving the extremity’s function. This study assesses the functional and oncological outcomes grade 3 GCTB with an extended intralesional curettage combined with adjuvant therapies comprising high-speed burring and bone cementation, instead of a wide excision, to better avoid limb salvage surgery with endoprosthetic reconstruction.

The Journal of Orthopedic Oncology offers information in all aspects of primary, malignant tumors. Osteosarcoma, Ewing's sarcoma, chondrosarcoma, chordoma, and soft tissue sarcomas etc., it also deals with diagnostic methods, therapeutic approaches, clinical, laboratory research and reconstructive techniques.

The Journal includes a wide range of fields in its discipline to create a platform for the authors to make their contribution towards the journal and the editorial office promises a peer review process for the submitted manuscripts for the quality of publishing.

The Journal uses Editorial Tracking System for quality in review process. Editorial Manager is an online manuscript submission, review and tracking systems. Review processing is performed by the editorial board members of Orthopedics & Oncology or outside experts; at least two independent reviewer’s approval followed by editor approval is required for acceptance of any citable manuscript. Authors may submit manuscripts and track their progress through the system.

The Journal Considers Research article, Review articles, editorial, letter, case reports, short communications, original articles from leading scientists and scholars around the world in all areas of related to Malignantosteoid, Multilobular tumour of bone, Chondrosarcoma, Chordoma, Osteosarcoma, Ewing's sarcomaetc., which come under the scope of the journal.

You may submit your manuscript as an e-mail attachment to the Editorial Office at  orthooncol@scholarlymed.com, orthooncol@orthopaedicsjournals.com

Best Regards,

Stella

Editorial Team

Journal of Orthopedic Oncology

WhatsApp: +44-1470-490003